205 related articles for article (PubMed ID: 15558048)
1. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity.
Shen L; Evel-Kabler K; Strube R; Chen SY
Nat Biotechnol; 2004 Dec; 22(12):1546-53. PubMed ID: 15558048
[TBL] [Abstract][Full Text] [Related]
2. Knocking the SOCS1 off dendritic cells.
Gilboa E
Nat Biotechnol; 2004 Dec; 22(12):1521-2. PubMed ID: 15583655
[No Abstract] [Full Text] [Related]
3. Silenced suppressor of cytokine signaling 1 (SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro.
Shi D; Li D; Yin Q; Qiu Y; Yan H; Shen Y; Lu G; Liu W
Immunol Res; 2015 Mar; 61(3):206-18. PubMed ID: 25381480
[TBL] [Abstract][Full Text] [Related]
4. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
[TBL] [Abstract][Full Text] [Related]
5. Keeping DCs awake by putting SOCS1 to sleep.
Kobayashi T; Yoshimura A
Trends Immunol; 2005 Apr; 26(4):177-9. PubMed ID: 15797506
[TBL] [Abstract][Full Text] [Related]
6. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells.
Song XT; Evel-Kabler K; Rollins L; Aldrich M; Gao F; Huang XF; Chen SY
PLoS Med; 2006 Jan; 3(1):e11. PubMed ID: 16381597
[TBL] [Abstract][Full Text] [Related]
7. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling.
Evel-Kabler K; Song XT; Aldrich M; Huang XF; Chen SY
J Clin Invest; 2006 Jan; 116(1):90-100. PubMed ID: 16357940
[TBL] [Abstract][Full Text] [Related]
8. Induction of hyper Th1 cell-type immune responses by dendritic cells lacking the suppressor of cytokine signaling-1 gene.
Hanada T; Tanaka K; Matsumura Y; Yamauchi M; Nishinakamura H; Aburatani H; Mashima R; Kubo M; Kobayashi T; Yoshimura A
J Immunol; 2005 Apr; 174(7):4325-32. PubMed ID: 15778397
[TBL] [Abstract][Full Text] [Related]
9. The role of suppressor of cytokine signaling 1 as a negative regulator for aberrant expansion of CD8alpha+ dendritic cell subset.
Tsukada J; Ozaki A; Hanada T; Chinen T; Abe R; Yoshimura A; Kubo M
Int Immunol; 2005 Sep; 17(9):1167-78. PubMed ID: 16091384
[TBL] [Abstract][Full Text] [Related]
10. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
11. Induction of CML28-specific cytotoxic T cell responses using co-transfected dendritic cells with CML28 DNA vaccine and SOCS1 small interfering RNA expression vector.
Zhou H; Zhang D; Wang Y; Dai M; Zhang L; Liu W; Liu D; Tan H; Huang Z
Biochem Biophys Res Commun; 2006 Aug; 347(1):200-7. PubMed ID: 16815301
[TBL] [Abstract][Full Text] [Related]
12. A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells.
Wang Y; Wang S; Ding Y; Ye Y; Xu Y; He H; Li Q; Mi Y; Guo C; Lin Z; Liu T; Zhang Y; Chen Y; Yan J
Clin Vaccine Immunol; 2013 Sep; 20(9):1449-56. PubMed ID: 23885028
[TBL] [Abstract][Full Text] [Related]
13. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
14. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of antigen-presentation attenuators to augment vaccines.
Evel-Kabler K; Chen SY
Curr Opin Mol Ther; 2006 Feb; 8(1):24-30. PubMed ID: 16506522
[TBL] [Abstract][Full Text] [Related]
16. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.
Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M
Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073
[TBL] [Abstract][Full Text] [Related]
17. A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity.
Williams P; Bouchentouf M; Rafei M; Romieu-Mourez R; Hsieh J; Boivin MN; Yuan S; Forner KA; Birman E; Galipeau J
J Immunol; 2010 Dec; 185(12):7358-66. PubMed ID: 21076067
[TBL] [Abstract][Full Text] [Related]
18. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
20. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
